Literature DB >> 17285098

Atypical antipsychotics and pituitary neoplasms in the WHO database.

P Murali Doraiswamy1, Gisela Schott, Kristina Star, Ralph Edwards, Bruno Mueller-Oerlinghausen.   

Abstract

Amisulpride and risperidone are potent dopamine D2 receptor blocking atypical antipsychotics that can cause hyperprolactinemia. Preclinical evidence shows that chronic administration of antipsychotics can cause pituitary adenomas in female mice. To investigate the clinical relevance in this finding, reports of pituitary neoplasms in the WHO adverse drug reaction (ADR) database were reviewed. Amisulpride and risperidone [corrected] had among the highest Information Component (IC) scores for benign pituitary neoplasm; amisulpride (IC = 3.31, IC025 = 1.83, 5 reports) and risperidone (IC = 4.03, IC025 = 3.33, 19 reports), and not otherwise specified (NOS) pituitary neoplasm: amisulpride (IC = 2.69, IC025 = 0.70, 3 reports) and risperidone (IC = 4.49, IC025 = 3.86, 23 reports). We conclude that there is a need for prospective studies to confirm causality and suggest that clinicians, until then, would consider a pituitary adenoma in patients experiencing severe hyperprolactinemia or associated symptoms when receiving potent D2 antagonists [corrected]

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285098

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  2 in total

1.  Regarding "A Risperidone-induced Prolactinoma Resolved When A Woman with Schizoaffective Disorder Switched to Ziprasidone: A Case Report".

Authors:  Danielle Coppola; Shanker Thiagarajah; Hong Qiu; David Hough
Journal:  Innov Clin Neurosci       Date:  2013-02

2.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.